Wednesday, 18 June 2025
This website uses cookies. By using our site you agree to our privacy policy
Username:
Password:
Lost username/password
Create an account
  • Home
  • About Us
    • Accreditation
    • Contact Us
  • Newsletters
  • Continuing Education
    • Diffuse Large B-cell Lymphoma
    • Follicular Lymphoma
    • CLL in Rural America
    • Multidisciplinary Perspectives on BTK Inhibitors Adverse Events Management in CLL and MCL

Tim Illidge, BSc, PhD, MRCP, FRCR, FRCPath

Professor of Targeted Therapy and Oncology
School of Cancer and Imaging Sciences
University of Manchester
Manchester Academic Health Science Centre
Manchester Cancer Research Centre
The Christie NHS Foundation Trust
Manchester, United Kingdom
Last modified: November 26, 2018
Authored Items
Does radiotherapy remain an important component in the standard of care for patients with early stage Hodgkin lymphoma?
Tim Illidge, BSc, PhD, MRCP, FRCR, FRCPath
FAQ published on April 9, 2014
What are the most common adverse events associated with brentuximab vedotin?
Tim Illidge, BSc, PhD, MRCP, FRCR, FRCPath
FAQ published on January 15, 2014
What is the role of imaging biomarkers using FDG-PET in the treatment of early-stage Hodgkin lymphoma?
Tim Illidge, BSc, PhD, MRCP, FRCR, FRCPath
FAQ published on August 21, 2013
Where does brentuximab vedotin fit into the management of patients with Hodgkin lymphoma within the European Union?
Tim Illidge, BSc, PhD, MRCP, FRCR, FRCPath
FAQ published on August 21, 2013
Role of Radiation Therapy in the Treatment of Hodgkin Lymphoma
Tim Illidge, BSc, PhD, MRCP, FRCR, FRCPath
12th ICML Highlights in Lymphoma published on July 12, 2013

MediCom Worldwide, Inc. Links

ManagingAML.com | ManagingMyeloma.com | ManagingMDS.com | ManagingMPN.com | PracticalOncologist.com | PracticalHematologist.com | ManagingCVD.com | ManagingSCD.com | MediComWorldwide.com

©2025 MediCom Worldwide, Inc. All rights reserved

  • Privacy, Terms, and Conditions
  • Contact Us